Market Analysis and Patient Sub-segment Identification for Glioblastoma Multiforme (GBM) Entry Strategy

Xuan Lu

2023-10-25

Background Research

Introduction

This report offers a comprehensive analysis of the Glioblastoma Multiforme (GBM) therapeutic area to facilitate our client's decision-making process as they contemplate entering this specialized field. Our primary focus is on understanding the structure of the GBM market, specifically identifying clinically significant patient subgroups that receive distinct treatments. The ultimate objective is to unveil distinct opportunities within this challenging and critical medical landscape.

GBM Overview

Glioblastoma Multiforme (GBM) stands as the most common and aggressive primary malignant brain tumor in adults. It originates from glial cells in the brain, particularly astrocytes. GBM is characterized by its highly invasive nature, rapid growth rate, and a high recurrence rate, making it a formidable challenge to treat. The standard treatment protocol includes surgery, radiation, and chemotherapy, with Temozolomide being a common chemotherapy drug. Despite aggressive treatment, prognosis remains bleak, with a median survival of 12-15 months.

Market Landscape

Given the poor prognosis and limited efficacy of current treatments, there's a notable unmet need for new therapies in the GBM market. Numerous pharmaceutical and biotech companies are conducting research on new treatments, encompassing targeted therapies, immunotherapies, and personalized medicine approaches. Clinical trials are underway to evaluate various novel agents and treatment modalities.

Potential Market Opportunities

- Development of drugs with the ability to effectively cross the blood-brain barrier (BBB).
- Targeted therapies based on molecular and genetic profiling of tumors.
- Immunotherapies designed to engage the immune system to recognize and attack GBM cells.
- Advanced drug delivery systems, such as nanoparticles or convection-enhanced delivery.

Market Analysis

Market Risks

- Stringent regulatory pathways due to the aggressive nature of GBM and past drug development failures.
- Challenges in clinical trial design related to the heterogeneity of the disease.
- Competition from existing and emerging therapies.
- Payer and reimbursement challenges due to the high costs of cancer therapies.

Competitive Landscape & Ongoing Clinical Trials

- Evaluation of current treatments, including surgery, radiation, and chemotherapy (Temozolomide).
- Identification of industry leaders, their drug candidates, and market share.
- Focused analysis on late-stage clinical trials and recent trends.
- Examination of trial results, particularly notable successes and failures.

Collaboration Opportunities & Regulatory Considerations

- Exploration of potential partnerships with research institutions, pharmaceutical, and biotech companies.
- Engagement with patient organizations.
- Thorough review of FDA and EMA guidelines for oncology drug approvals.
- Comprehension of expedited pathways such as Breakthrough Therapy and Fast Track.

Market Insights The cost of existing treatments varies significantly, ranging from surgical procedures and radiation therapy to chemotherapy drugs like Temozolomide. Costs are influenced by factors like insurance coverage, geographic location, and treatment duration. Additionally, the introduction of innovative therapies, including Tumor Treating Fields (TTF) through devices like Optune, adds complexity to the market.

Descriptive Statistics

```
## [1] "Summary statistics for numeric variables:"
```

	mean	sd	min	max	range
year_of_birth	1957.89867	12.03191	1925	1996	71
age_at_diagnosis	56.89733	12.23071	19	88	69
pct_of_tumor_mass_surgically_resected	70.09890	24.27528	10	100	90

```
## [1] "Frequency table for categorical variables:"
```

Variable	Categories	Count	Percent
country	US	750	100%
line_of_therapy	1L	300	40%
line_of_therapy	2L	450	60%
gender	Female	259	35%
gender	Male	491	65%
race	Asian	30	4.0%
race	Black/African	110	14.7%
race	Other	3	0.4%
race	Spanish/Hispanic/Latino	44	5.9%
race	White/Caucasian	563	75.1%

Variable	Categories	Count	Percent
adequate_caretaker_support	No	209	28%
adequate_caretaker_support	Unknown	49	7%
adequate_caretaker_support	Yes	492	66%
patient_travel_time_lt30min	No	408	54%
patient_travel_time_lt30min	Unknown	46	6%
patient_travel_time_lt30min	Yes	296	39%
patient_level_of_involvement	Active / knowledgeable / questioning	292	39%
patient_level_of_involvement	Average level of engagement with the disease	382	51%
patient_level_of_involvement	Passive / not interested / unengaged	76	10%
patient_treatment_goals	More focused on Quality of Life	235	31%
patient_treatment_goals	More focused on Survival	515	69%
primary_insurance	Exchange	6	0.80%
primary_insurance	HMO	241	32.13%
primary_insurance	Medicaid	59	7.87%
primary_insurance	Medicare	187	24.93%
primary_insurance	Other	1	0.13%
primary_insurance	PPO	194	25.87%
primary_insurance	Uninsured	7	0.93%
primary_insurance	Unknown	45	6.00%
primary_insurance	VA/Other government	10	1.33%
comorbidity_renal_impairment	No	671	89%
comorbidity_renal_impairment	Yes	79	11%
comorbidity_anemia	No	633	84%
comorbidity_anemia	Yes	117	16%
comorbidity_copd_pulmonary	No	664	89%
comorbidity_copd_pulmonary	Yes	86	11%
comorbidity_diabetes	No	612	82%
comorbidity_diabetes	Yes	138	18%
comorbidity_chf_cong_heart_failure	No	708	94%
comorbidity_chf_cong_heart_failure	Yes	42	6%
comorbidity_neuropathies	No	703	94%
comorbidity_neuropathies	Yes	47	6%
comorbidity_other_neurological	No	733	98%
comorbidity_other_neurological	Yes	17	2%
comorbidity_hepatic_insufficiency	No	730	97%
comorbidity_hepatic_insufficiency	Yes	20	3%
comorbidity_other_cytopenia	No	727	97%
comorbidity_other_cytopenia	Yes	23	3%
comorbidity_autoimmune_disorder	No	732	98%
comorbidity_autoimmune_disorder	Yes	18	2%
comorbidity_hypertension	No	570	76%
comorbidity_hypertension	Yes	180	24%
comorbidity_other_cardiovascular	No	702	94%
comorbidity_other_cardiovascular	Yes	48	6%
comorbidity_alzheimer	No	740	99%
comorbidity_alzheimer	Yes	10	1%
comorbidity_other_cancer_notgbm	No	738	98%
comorbidity_other_cancer_notgbm	Yes	12	2%
comorbidity_other_specify	No	737	98%
comorbidity_other_specify	Yes	13	2%
comorbidity_other_specify_1		742	99%
comorbidity_other_specify_1	aortic aneurysm	1	0%

Variable	Categories	Count	Percent
comorbidity_other_specify_1	arthritis	1	0%
comorbidity_other_specify_1	bipolar	1	0%
comorbidity_other_specify_1	disc disease	1	0%
comorbidity_other_specify_1	elevated cholesterol, Herniated disc s/p surgery	1	0%
comorbidity_other_specify_1	obese	1	0%
comorbidity_other_specify_1	obesity	1	0%
comorbidity_other_specify_1	parkinson's disease	1	0%
comorbidity_none	No	395	52.7%
comorbidity_none	Yes	355	47.3%
ecog_at_1st_line	ECOG 0	165	22.0%
ecog_at_1st_line	ECOG 1	377	50.3%
ecog_at_1st_line	ECOG 2	118	15.7%
ecog_at_1st_line	ECOG 3	13	1.7%
ecog_at_1st_line	ECOG 4	77	10.3%
ecog_at_2nd_line	ECOG 0	72	9.6%
ecog_at_2nd_line	ECOG 1	155	20.7%
ecog_at_2nd_line	ECOG 2	170	22.7%
ecog_at_2nd_line	ECOG 3	48	6.4%
ecog_at_2nd_line	ECOG 4	5	0.7%
ecog_at_2nd_line	Unknown	300	40.0%
mgmt_methylated	No	279	37.2%
mgmt_methylated	Unknown	259	34.5%
mgmt_methylated	Yes	212	28.3%
egfr_mutated	No	201	26.8%
egfr_mutated	Unknown	386	51.5%
egfr_mutated	Yes	163	21.7%
tp53_mutated	No	183	24.4%
tp53_mutated	Unknown	442	58.9%
tp53_mutated	Yes	125	16.7%
idh1_idh2_mutated	No	173	23%
idh1_idh2_mutated	Unknown	486	65%
idh1_idh2_mutated	Yes	91	12%
pd_l1_overexpressed	No	162	21.6%
pd_l1_overexpressed	Unknown	482	64.3%
pd_l1_overexpressed	Yes	106	14.1%
regimen_in_1st_line	Avastin + Irinotecan	56	7.47%
regimen_in_1st_line	Avastin + Lomustine	12	1.60%
regimen_in_1st_line	Avastin + TMZ	26	3.47%
regimen_in_1st_line	Avastin mono	171	22.80%
regimen_in_1st_line	Gliadel wafers	4	0.53%
regimen_in_1st_line	Lomustine mono	116	15.47%
regimen_in_1st_line	Other	2	0.27%
regimen_in_1st_line	TMZ mono	363	48.40%
regimen_in_1st_line_other		748	100%
regimen_in_1st_line_other	Irinotecan	1	0%
regimen_in_1st_line_other	lomustine	1	0%
regimen_in_2nd_line	Avastin + Irinotecan	86	11.47%
regimen_in_2nd_line	Avastin + Lomustine	48	6.40%
regimen_in_2nd_line	Avastin + TMZ	72	9.60%
regimen_in_2nd_line	Avastin mono	130	17.33%
regimen_in_2nd_line	Gliadel wafers	2	0.27%
regimen_in_2nd_line	Lomustine mono	41	5.47%

Variable	Categories	Count	Percent
regimen_in_2nd_line	Other	2	0.27%
regimen_in_2nd_line	TMZ mono	69	9.20%
regimen_in_2nd_line	Unknown	300	40.00%
regimen_in_2nd_line_other		748	100%
regimen_in_2nd_line_other	bevacizumab	1	0%
regimen_in_2nd_line_other	cyberknife and temozolomide	1	0%

Discussion Questions